Vanda Pharmaceuticals Inc. stock is up 11.14% since 30 days ago. The next earnings date is Feb 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 17 December’s closed higher than November.
Vanda Pharmaceuticals Inc. focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders. Its products under development include Fanapt (iloperidone) and Tradipitant (VLY-686) The company markets its products in the United States, Europe, and Israel.